State of Wyoming’s Pliant Therapeutics PLRX Stock Holding History

State of Wyoming’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-747	Closed	-$10K	–	1976
2021 Q4	$10K	Buy	747 +131	+21%	+$2.08K	﹤0.01%	1668
2021 Q3	$10K	Sell	616 -366	-37%	-$7.77K	0.01%	1029
2021 Q2	$29K	Buy	982 +572	+140%	+$17.8K	0.02%	861
2021 Q1	$16K	Buy	+410	New	+$13.3K	0.03%	344

Other funds holding PLRX

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

State of Wyoming's PLRX Position: Q1 2022 in Review

State of Wyoming sold out of Pliant Therapeutics (PLRX) in Q1 2022, closing a stake of 747 shares — an estimated $10K sold.

State of Wyoming first reported a position in PLRX in Q1 2021 and held it in 4 quarters. The position peaked at $29K in Q2 2021. 92 funds tracked by Wall St. Rank hold PLRX as of Q1 2022.

State of Wyoming reported no remaining Pliant Therapeutics position as of Q1 2022 after selling out during the quarter.
State of Wyoming sold 747 Pliant Therapeutics shares in Q1 2022, an estimated $10K.
State of Wyoming first reported a position in Pliant Therapeutics in Q1 2021 and held it in 4 quarters.
State of Wyoming's Pliant Therapeutics position peaked at $29K in Q2 2021.
92 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2022.

Based on State of Wyoming's 13F filing for Q1 2022, filed 13 May 2022.